2017 ACR/ARHP Annual Meeting Archives - Page 63 of 201

Abstract Number: 389

S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities
Abstract Number: 390

S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities
Abstract Number: 2227

S100A9 Induces a Pain Response during Experimentally Induced Acute Synovitis
Abstract Number: 612

Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period
Abstract Number: 1196

Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial
Abstract Number: 725

Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
Abstract Number: 1889

Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the “Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months” Extension Study
Abstract Number: 1532

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year
Abstract Number: 2886

Safety and Efficacy of Long-Time Intensified Rituximab Treatment in Patients with Systemic Sclerosis
Abstract Number: 620

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Abstract Number: 2396

Safety and Humoral and Cell-Mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis
Abstract Number: 778

Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
Abstract Number: 2271

Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Abstract Number: 2277

Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Abstract Number: 322

Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Abstract Number: 2581

Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus
Abstract Number: 2126

Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease
Abstract Number: 1755

Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Abstract Number: 2585

Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
Abstract Number: 511

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
Abstract Number: 1907

Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Abstract Number: 2592

Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Abstract Number: 2607

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Intravenous and Subcutaneous Single or Multiple Doses in Healthy Volounters and Subjects with Active SLE
Abstract Number: 544

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
Abstract Number: 2907

Salivary Gland Enlargement in IgG4-Related Disease Is Associated with Multiorgan Involvement and Higher Basal Disease Activity
Abstract Number: 1487

Salivary Gland Ultrasonography (SGUS) and Subclinical Parotid Involvement: Usefulness of Sgus in the Identification of a Subset of Patients with Sjögren’s Syndrome at Higher Risk for Extraglandular Disease Manifestations
Abstract Number: 558

Salivary Syndecan-1 Levels Are Associated with Salivary Gland Dysfunction and Immune Dysregulation in Patients with Sjögren’s Syndrome
Abstract Number: 28

Sapril and Sbcma As Potential Biomarkers of B Cell Hyperactivation in Rheumatoid Arthritis: A Cluster Analysis Approach
Abstract Number: 2457

Sarilumab for the Treatment of Active, Moderate-to-Severe Rheumatoid Arthritis (RA): An Analysis of Cost per Effectively Treated Patient
Abstract Number: 748

Scleromyxedema Phenotype Pre- and Post-Treatment with Intravenous Immunoglobulin
Abstract Number: 1231

Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence
Abstract Number: 1086

Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 1651

Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Abstract Number: 823

Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Abstract Number: 176

SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis
Abstract Number: 2247

Secondary Fibromyalgia Is Not Associated with Higher Likelihood of Patient-Physician Discordance in Global Assessment in Patients with Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 46

Secondary Light Chain Editing and Allelic Inclusion in Antibody Secreting Cells from the Minor Salivary Gland
Abstract Number: 2044

Secondary Prevention of Cardiovascular Disease Is Incomplete in a Systemic Lupus Erythematosus Population-Based Cohort
Abstract Number: 1826

Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Abstract Number: 2546

Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Abstract Number: 1529

Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
Abstract Number: 606

Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Abstract Number: 3L

Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Abstract Number: 1523

Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Abstract Number: 1528

Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue
Abstract Number: 621

Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Abstract Number: 1828

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Abstract Number: 622

Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Abstract Number: 618

Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Abstract Number: 607

Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Abstract Number: 328

Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Abstract Number: 2577

Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells
Abstract Number: 698

Selected Nailfold Videocapillaroscopy Changes Are Linked to SLE Onset in a Cohort of Uctd Subjects
Abstract Number: 1346

Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients
Abstract Number: 407

Selective Inhibition of Tfh Cells By a Small Molecule Inhibitor Abrogates Progression of Experimental Inflammatory Arthritis
Abstract Number: 81

Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis
Abstract Number: 1834

Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Abstract Number: 2685

Sensitivity and Specificity of YKL-40 for the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 810

Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data
Abstract Number: 802

Sensorineural Hearing Loss in Takayasu’s Arteritis
Abstract Number: 949

Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis
Abstract Number: 952

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Lymphocyte Homeostasis In Vivo and Its Deficiency Associates with Lymphopenia in SLE Patients
Abstract Number: 1743

Serine Arginine/Rich Splicing Factor 1 (SRSF1) Increases IL-2 Production in T Cells By Increasing the Expression of NFAT and c-Fos
Abstract Number: 2569

Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis
Abstract Number: 2410

Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study
Abstract Number: 2785

Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Abstract Number: 1785

Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Abstract Number: 771

Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Abstract Number: 805

Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Abstract Number: 332

Serum 25-Hydroxyvitamin D, Acute Phase Reactants and Disease Activity in Rheumatologic Diseases
Abstract Number: 1843

Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)
Abstract Number: 286

Serum Amyloid a Aggravates Rheumatoid Arthritis By Activating NFAT5-Mediated Migration of Macrophages
Abstract Number: 691

Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
Abstract Number: 875

Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736
Abstract Number: 421

Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Abstract Number: 2903

Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Abstract Number: 1664

Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients
Abstract Number: 1380

Serum Galectin-3 in Rheumatoid Arthritis Compared with Healthy Controls and Subjects with Prediabetes before and after High-Intensity Interval Training
Abstract Number: 782

Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 1895

Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Abstract Number: 2728

Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Abstract Number: 426

Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
Abstract Number: 2150

Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Abstract Number: 1774

Serum Periostin As a Biomarker in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1389

Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Abstract Number: 2863

Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Abstract Number: 1431

Serum Trough Levels of Adalimumab Inversely Correlate with Disease Activity in Patients with Inflammatory Arthritis
Abstract Number: 2080

Serum Uric Acid and Incident Dementia: A Population Based Study
Abstract Number: 694

Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Abstract Number: 538

Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Abstract Number: 2773

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Abstract Number: 2359

Severity of Ischemic and Hemorrhagic Stroke in Patients with Rheumatoid Arthritis Compared with the General Population
Abstract Number: 1006

Sex Differences in Depressive Symptom Subtypes in Knee Osteoarthritis
Abstract Number: 1109

Sex Differences in Gout Patients: Epidemiology, Flares and Hospitalization Data in a Population Based Cohort
Abstract Number: 1816

Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Abstract Number: 1501

Sexual Dysfunction and Vaginal Dryness Are Common in Female Patients with Early, Active Primary Sjogren’s Syndrome
Abstract Number: 1637

Sexual Function in Married Indian Women with Systemic Lupus Erythematosus
Abstract Number: 2563

SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Abstract Number: 1526

Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Abstract Number: 2857

Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis
Abstract Number: 780

Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
Abstract Number: 635

Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Abstract Number: 366

Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Abstract Number: 1598

Shrinking Lung Syndrome in Systemic Lupus Erythematosus Patients: A Diagnosis We Should Suspect More Often
Abstract Number: 570

Signalling Pathways Identified in Salivary Glands from Primary Sjögren’s Syndrome Patients Reveal Enhanced Adipose Tissue Development, As Demonstrated By Microarray Analysis, Real-Time PCR and Immunohistochemistry
Abstract Number: 1682

Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing
Abstract Number: 2869

Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Abstract Number: 13L

Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial
Abstract Number: 1069

Significantly Elevated Serum Protein-Adduction with 4-Hydroxy-2-Nonenal but Not Malondialdehyde in Sjogren’s Syndrome
Abstract Number: 2464

Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life
Abstract Number: 1509

Similarities and Differences between Non-Radiographic and Radiographic Axial Spondyloarthritis
Abstract Number: 1510

Similarities and Differences between Osteitis Condensans Ilii and Axial Spondyloarthritis Patients Presenting with Chronic Back Pain in a Rheumatology Setting
Abstract Number: 1506

Similarities and Differences between Patients Fulfilling Non-Radiographic Axial Spondyloarthritis and Undifferentiated Spondyloarthritis Criteria: Results from the Esperanza Cohort
Abstract Number: 2004

Simplified Assessment in Capillaroscopy
Abstract Number: 26

Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Abstract Number: 2703

Single Cell Analysis of TCRs from CD8+ T Cells in Sjogren’s Syndrome
Abstract Number: 31

Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 832

Single Cell Analysis Reveals Heterogeneity of Type I IFN Gene Expression in Developing Autoreactive B Cells
Abstract Number: 2657

Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established Systemic Lupus Erythematosus (SLE)-Risk Loci in Lupus Patient Monocytes
Abstract Number: 1923

Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin
Abstract Number: 2324

Single Cell RNA-Sequencing of Bone Marrow Macrophages Identifies a Distinct Subpopulation in Systemic JIA with Features of Interferon Response, Endocytic Vesicles and Phagocytosis
Abstract Number: 1711

SIRT1 May Protect Against Systemic Sclerosis-Related Pulmonary Fibrosis By Decreasing Pro-Inflammatory and Pro-Fibrotic Processes
Abstract Number: 2963

Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Abstract Number: 2473

Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
Abstract Number: 2303

Six Minute Walk Test in Childreh with Juvenile Idiopathic Arthritis: Normative Values, Prediction Equation, and Comparison to Healthy Children
Abstract Number: 1381

Skeletal Muscle Cytokine and Myostatin Responses to High-Intensity Interval Training in Rheumatoid Arthritis Contrasted with Prediabetes Mellitus
Abstract Number: 1717

Skin Commensal Bacteria Might Affect Wound Repair in SSc By Preventing Fibroblast Activation and By Provoking Chronic Inflammatory Reaction
Abstract Number: 2704

Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Abstract Number: 1632

SLE Characteristics Associated with Modified Framingham Risk Score in Patients without Clinical Cardiovascular Disease
Abstract Number: 1675

SLE Comprises Four Immune-Phenotypes, Which Differ Regarding HLA-DRB1 and Clinical Associations
Abstract Number: 1624

SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Abstract Number: 1657

SLE Patients with Active Interferon Pathways Showed More Systemic Disease Involvement Than Patients with Inactive Interferon Pathways
Abstract Number: 2824

Sleep and Depression Mediate the Relationship between Pain and Cognitive Dysfunction in Lupus Patients
Abstract Number: 1398

Sleep and Physical Activity: An Objective Profile of People with Rheumatoid Arthritis
Abstract Number: 1649

Sleep Disturbances in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1640

SLICC Damage Index Is Associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsies
Abstract Number: 1368

Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis
Abstract Number: 1764

Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Abstract Number: 467

Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid Arthritis
Abstract Number: 124

Smoking and Rheumatoid Arthritis Susceptibility; Quantification of the Impact of Cumulative Dose, Frequency and Duration of Smoking, and Smoking Cessation
Abstract Number: 786

Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 1683

Smoking Behaviour and the Progression of Organ Manifestations in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study
Abstract Number: 126

Smoking Is Causally Associated with Disease Activity in Rheumatoid Arthritis
Abstract Number: 1447

Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Abstract Number: 1007

Smoking Signicantly Reduces Effectiveness and Long-Term Survival of Biologic Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 218

Social Factors and Racial Disparities in Total Hip Arthroplasty Outcomes
Abstract Number: 441

Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Abstract Number: 846

Social Support in Couples-Focused Physical Activity Interventions for People with Hip or Knee Osteoarthritis: What Kinds of Partner Support Are Associated with Increases in Physical Activity and Reductions in Sedentary Behavior?
Abstract Number: 844

Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Abstract Number: 1665

Soluble Programmed Cell Death Protein 1 As a Biomarker for Systemic Lupus Erythematosus
Abstract Number: 454

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Abstract Number: 677

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 2809

Spatial Navigation Impairment Associated with Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus
Abstract Number: 30

Specificity of Salivary Gland-Derived Monoclonal Antibodies from Sjogren’s Syndrome Patients Using Human Proteome Arrays
Abstract Number: 1164

Spectrum of Skin Eruption and Histological Findings in Adult-Onset Still’s Disease and Significance of Atypical Persistent Skin Eruptions
Abstract Number: 1790

Sphingosine -1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE
Abstract Number: 2560

Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells
Abstract Number: 484

Sputum Neutrophils Demonstrate Increased Neutrophil Extracellular Trap Formation in RA-Free Subjects at-Risk of Future RA
Abstract Number: 690

SSA Antibodies Are Associated with Valvular Abnormalities in SLE Patients without Clinical Cardiovascular Disease
Abstract Number: 1262

Stability of Two Short Medication Adherence Questionnaires over Time for Follow-up in Patients with Rheumatoid Arthritis
Abstract Number: 1088

Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Abstract Number: 1451

Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Abstract Number: 2928

STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis
Abstract Number: 1661

STAT4 Regulates Pathogenic IL-21 and IFN-γ in Tfh Cells in Murine and Human Lupus
Abstract Number: 2077

Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Abstract Number: 2149

Statin Use in a Longitudinal Cohort of Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1688

Stem Cell-Enriched Lipotransfer Substantially Improves Measures of Appearance and Function Due to Facial Fibrosis in Systemic Sclerosis
Abstract Number: 1414

Stimulation with Resistin Upregulates Chemokine Production By Fibroblast-like Synoviocytes from Patients with Rheumtoid Arthritis
Abstract Number: 939

Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients
Abstract Number: 660

Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Abstract Number: 491

Streptococcus Species Enriched in the Oral Cavity of RA Patients: A Persistent Source of Peptidoglycan-Polysaccharide Polymers Which Drive Disseminated Synovial Inflammation
Abstract Number: 1967

Strongyloides Screening in Immunocompromised Immigrant Rheumatology Patients
Abstract Number: 2019

Structural Abnormalities in the Knee Detected By MRI in Middle-Aged Subjects without Radiographic Knee Osteoarthritis
Abstract Number: 2964

Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Abstract Number: 2762

Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Abstract Number: 1535

Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Abstract Number: 2855

Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Abstract Number: 2590

Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Abstract Number: 17L

Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study
Abstract Number: 573

Subepithelial Infiltrate of the Vagina in Primary Sjogren’s Syndrome: The Cause of Vaginal Dryness?
Abstract Number: 1025

Submetabolome Profiling with Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolite Profile with 99% Accuracy for Rheumatoid Arthritis
Abstract Number: 1842

Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Abstract Number: 2288

Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)
Abstract Number: 2261

Supporting Smoking Cessation in RA and SLE: Identifying Patient-Centered Outcomes
Abstract Number: 2729

Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Abstract Number: 2265

Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Abstract Number: 727

Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Abstract Number: 1002

Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Abstract Number: 2490

Sustained Clinical Response in Refractory Rheumatoid Arthritis Patients with a Low-Dose Rituximab Retreatment Regimen. a Single Center Experience
Abstract Number: 1820

Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Abstract Number: 1929

Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired By Aggrecan, in a Rat Model of Osteoarthritis
Abstract Number: 2802

Sustained Remission of Inflammation Is Associated with Reduced Structural Damage on SI Joint MRI in Patients with Early Axial Spa: Evidence to Support the Concept of Treat-to-Target
Abstract Number: 1905

Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Abstract Number: 2471

Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Abstract Number: 2879

Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 2439

Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 1430

Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Abstract Number: 1348

Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort
Abstract Number: 1178

Sympathetic Joint Effusion in an Urban Hospital
Abstract Number: 728

Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Abstract Number: 2315

Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Abstract Number: 2894

Synchronous Telemedicine Care in Rheumatology for a Dispersed Veterans Affairs Health System
Abstract Number: 890

Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE
Abstract Number: 1456

Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Abstract Number: 971

Synovial Fibroblast CD318 Expression Mediates T Cell Adhesion and Migration in Rheumatoid Arthritis
Abstract Number: 2081

Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia
Abstract Number: 1101

Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability
Abstract Number: 1052

Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Abstract Number: 2605

Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
Abstract Number: 1166

Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil
Abstract Number: 678

Systemic Hypertension Is Associated with Presence of Vascular Injury on Lupus Nephritis Renal Biopsies: A Retrospective Cohort Study
Abstract Number: 2197

Systemic Inflammation and Physical Function in Knee Osteoarthritis
Abstract Number: 2629

Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
Abstract Number: 2697

Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
Abstract Number: 2098

Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review